Key facts

Invented name
Fluad Tetra
Active Substance
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2)
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage)
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage)
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1)
Therapeutic area
Vaccines
Decision number
P/0355/2020
PIP number
EMEA-001715-PIP01-14-M04
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of influenza infection
Route(s) of administration
Intramuscular use
Contact for public enquiries

Seqirus Netherlands B.V.

Tel. +31 646951054
E-mail: pip.seq@seqirus.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

P/0355/2020 : EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2).....(EMEA-001715-PIP01-14-M04)

How useful do you find this page?